

Teaser Memorandum

TAEJOON PHARM Co.,Ltd.

Developing and Exporting of Anti glaucoma agent



Executive Summary

- TAEJOON PHARM Co., Ltd. founded in 1978, has grown to become an expert Pharmaceutical company with the advanced technology in ophthalmic agents and Contrast Media and the resources have made endless endeavor on research & development.
- □ For the ophthalmic products by insuring people a bright sight with our ophthalmic solutions and ointments. we tried hard to improve the quality of human life. As a part of this effort, we introduced Azelan Ophthalmic Solutions and we presented people suffering from glaucoma with the hope, Xalost and Xaloscom.
- TAEJOON PHARM Co., Ltd. intends to enter into a technology transfer or licensing transaction with regard to anti-glaucoma agent. Terms of the transaction are not set, and interested parties may further discuss the details if they wish to enter into an agreement.

Industry Sector :

Pharmaceutical

Therapeutic Target :

Ophthalmic pharmaceuticals

State of Development :

Mass production stage

Key Technology Highlights

- □ The glaucoma medicines being placed on the market have the purpose of preventing the destruction of the optic nerve by decreasing the intraocular pressure. The excellence of a product can be evaluated with the effect of the decrease of the intraocular pressure and with patient's adaptability based on the frequency of eye drops application.
- □ The eye drop with the timolol ingredients had been the medicine for the standard therapy for the glaucoma treatment before the eye drops with the latanoprost ingredients were developed. The xalost eye drops have the outstanding effect of the decrease of he intraocular pressure and is the product with patient's adaptability increased by one time administration a day.

Performance Category	Xalost Eye Drops	Domestic Similar Competitive Products (Timoptic-XE 0.25% Eye Drops)	
Outstanding effectiveness as the prostaglandin derivative	• Latanoprost : Showing the better effect than timolol because the patients with the intraocular pressure decreased by 4.0mmHg after 6 months reaches 73%	• Timolol maleate: The patients with the intraocular pressure decreased by 4.0mmHg after 6 months reaches 45%	
Administration Convenience	 Showing the greater decrease of the intraocular pressure than Timolol maleate with one time administration a day Latanoprost: The intraocular pressure decreased by 8.2mmHg in the 12th week (decreased by 30%) 	 Showing the less intraocular pressure decrease than Latanoprost with two times administration a day Timolol maleate : The intraocular pressure decreased by 5.2mmHg in the 12th week (decreased by 20%) 	

IP Owner Summary

TaeJoon Pharm Co.,Ltd.

Personal Description of Researcher

- Name: Tae-young Lee
- Present Position: CEO/President TaeJoon Pharm Co.,Ltd.
- Office address:
 657-87 Hannam-dong, TAEJOON Bldg, Yongsan-gu, Seoul 140-210, Korea

Market Feasibility

Domestic and global market size:

- Domestic market size : 43.5 million dollars (in 2010)
- Global market size : 5.3 billion dollars (in 2010)
- Domestic and global market opportunity
 - (competitors and competing product):
 - Timoptic-XE Eye Drops 0.25%

Trend & Partnership

- Future outlook and trends related to technology : Ophthalmic drugs
- Technology Transfer and commercialization conditions : N/A
- Type of business relationship sought (including licensing availability) : Investment promotion



Technology Overview

Technology Platform

The core technology of TAEJOON PHARM Co., Ltd. is the method to manufacture the eye drops composite decreasing the side effect of the dry eye syndrome, increasing the solubility, and enabling the treatment of glaucoma. The soluble complex ophthalmic composites including the prostaglandin-series medicine activating the treatment of glaucoma, the polymer material, the surface-active agent, and the preservative and the methods to manufacture them are provided.

Background and unmet needs

Gaucoma constitutes the various impaired groups due to the increase of the intraocular pressure and is the disease causing the optic atrophy and the visual field defect. It is not single disease but is the impaired group consisting of various aspects showing various clinical and histopathological opinions. It is a generic term of the unique optic nerve disease of the glaucoma caused by the increase of the intraocular pressure and other various risk factors and the aspects showing the visual field defect caused by the death of the retina nerve knot cells.

The therapy of the current prostaglandin-series glaucoma drug is to apply the local administration to the optic mucous membrane. The dry eye syndrome frequently occurred as a side effect. Hence, two medicines such as a glaucoma medicine and artificial lacrima eye drops have been prescribed in parallel. Hence, there are the problems of the inconvenience of using two medicines separately, the increase of expenses, and the trouble of the way of consecutively administering the glaucoma medicine and the artificial lacrima so that the eye drops curing two diseases at a time by resolving it and the new complex eye drops possibly enhancing the effect of preventing the dry eye syndrome need to be developed.

The invention is concerned with helping to cure the dry eye occurring from the latanoprost which is the glaucoma medicine and from the side effect and the dystrophy epithelialis corneae caused by the dry eye and with providing the ophthalmic composite of the new glaucoma complex drug by adding the outstanding polymer material as the role of the medicine reservoir of the latanoprost.

Discovery and Achievements

The TAEJOON PHARM composite for eye drops application have the enhanced glaucoma curing effect by improving the dry eye syndrome and the outstanding curing effect as well.

It was verified that when the latanoprost and the sodium hyraluronate complex eye drops are applied to a rabbit, the latanoprost has the effect of qualitatively improving the precorneal tear film and promoting the treatment of cornea cut compared to the single application of the latanoprost.



Fig. 1. The graph showing the moisture evaporation quantity of the agar medium as time goes by.



Fig. 2. The graph comparing the effect of decreasing the intraocular pressure of the TAEJOON PHARM eye drops composite with the current glaucoma medicine.





Fig. 3. The graph representing the results of testing the eye irritation level of the TAEJOON PHARM eye drops composite.



Fig. 4. The graph showing the object with the dry spot occurring as time goes by after inducing the cut.

Patents and Publications

Country	Appln. No.	Status	Description	
Korea	0775065	Granted	Eyedrop composition for sustained release, and method of preparing the same	
Korea	0802534	Granted	Eyedrop composition having low irritation and method of preparing the same	
Korea	0845942	Granted	Eye composition with reduced side effects and method of preparing the same	
Korea	0938233	Granted	Eye composition containing a prostaglandin-based compound and method of preparing the same	
Korea	0963611	Granted	Eye composition comprising alginic acid based compounds and method of preparing the same	

Contact Point

KHIDI (Korea Health Industry Development Institute) is currently receiving inquiries from interested parties in this transaction. If you are interested, please contact any of the KHIDI professionals below :

Name	Title	Tel. number	E-mail address
Yong-U Kim	Business Development Manager	82-43-713-8842	gkimyw@gmail.com